Research Article
CD49b, a Major Marker of Regulatory T-Cells Type 1, Predicts the Response to Antiviral Therapy of Recurrent Hepatitis C after Liver Transplantation
Table 2
Demographic data of the cohort.
| Characteristics | Distribution |
| Cohort study | 27 patients | Inclusion date | August 2002 to January 2004 | Time after transplant (year)* | 3 (1, 8) | Age at selection* | 56 (27, 68) | Gender | | Male | 20 | Female | 7 | HCV genotype** | Gen 1: (67%), Gen 2: (4%) Gen 3: (18%), Gen 4: (11%) | Immunosuppression | Tacrolimus: (59%) Cyclosporine: (41%) | Metavir score at inclusion | : 2: 3: 4: | Prothrombin time (%) | | Mean | 90 ± 9 | Median (min; max) | 90 (59; 107) | AST/ALT (UI/L) | | (mean) | 75 ± 45/100 ± 60 | (median, min; max) | 58 (24; 196)/82 (32; 293) | Bilirubin blood level at inclusion (µmol/L) | 15.7 ± 10.2 | Viral load (log) | 6.59 ± 0.24 |
|
|
Median value (min, max)
**
= number of patients.
|